3 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Terminated 1 |
Follow avdoralimab: new trials by email Literature Review of avdoralimab trials Research Report on avdoralimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Avdoralimab (IPH5401), Control - Bullous Pemphigoid | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 15 | 2020-10-10 | 2026-03-24 |
| Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ) avdoralimab, Placebo - COVID | Phase 2 | Completed | Assistance Publique Hopitaux De Marseille | 208 | 2020-04-27 | 2021-05-27 |
| Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection Autophagy inhibitor (GNS651), Standard of care, Avdoralimab - SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor | Phase 2 | Completed | Centre Leon Berard | 19 | 2020-04-15 | 2022-09-30 |
| IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors IPH5401 and Durvalumab - Advanced Solid Tumors | Phase 1 | Terminated | Innate Pharma | 73 | 2018-09-07 | 2022-01-27 |
COVID-19 (1) · Infections (1) · Neoplasms (1) · Pemphigoid, Bullous (1)
Assistance Publique Hopitaux De Marseille (1) · Centre Hospitalier Universitaire de Nice (1) · Centre Leon Berard (1) · Innate Pharma (1)
France (4) · United States (1)
Emilie Garrido-Pradalie (1) · Passeron Thierry, PhD (1)